Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
50 results about "Histamine h" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Tetrahydroisoquinoline compounds
Certain tetrahydroisoquinoline compounds are histamine H3 receptor and serotonin transporter modulators useful in the treatment of histamine H3 receptor- and serotonin-mediated diseases.
Owner:JANSSEN PHARMA NV
Cyclopropyl amines as modulators of the histamine h3 receptor
ActiveUS20070066821A1Improve breathabilityImprove permeabilityOrganic active ingredientsSenses disorderHistamine H3 receptorHistamine h
Owner:JANSSEN PHARMA NV
Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
Certain diaryl-substituted tetrahydroisoquinoline compounds are histamine H3 receptor and / or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and / or serotonin-mediated diseases.
Owner:JANSSEN PHARMA NV
Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
Owner:JANSSEN PHARMA NV
Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
Certain diaryl-substituted tetrahydroisoquinoline compounds are histamine H3 receptor and / or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and / or serotonin-mediated diseases.
Owner:JANSSEN PHARMA NV
Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders
This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain non-imidazole tertiary amine derivatives and their salts and solvates. These compounds have H3 histamine receptor antagonist activity. This invention also relates to pharmaceutical compositions containing these compounds and to a method of treating disorders in which histamine H3 receptor blockade is beneficial.
Owner:ATHERSYS
Thieno-and furo-pyrimidine modulators of the histamine H4 receptor
Thieno- and furo-pyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as inflammation.
Owner:JANSSEN PHARMA NV
2-aminopyrimidine modulators of the histamine H4 receptor
Owner:JANSSEN PHARMA NV
Method for treatment of neurodegenerative diseases and effects of aging
InactiveUS7232830B2Increase neuronalIncrease neuronal metabolismBiocideNervous disorderAutoimmune diseaseMethyltransferase
A method for treatment of neurodegenerative disease conditions stemming from multiple sclerosis, aging, autoimmune diseases and fibromyalgia. A compound effective to increase neuronal metabolism of histamine to a histamine H2 agonist is administered in an amount sufficient to stimulate production of cyclic AMP at a level which is sufficient to maintain myelin against undergoing self-degeneration. The compound is selected from the group consisting of histamine M-methyltransferase, monoamineoxidase-A, monoamineoxidase-A agonists and histamine H3 antagonists. The histamine M-methyltransferase may be administered to increase neuronal metabolism of histamine to tele-methylhistamine, whereas the monoamineoxidase-A or monoamineoxidase-A agonist may be administered so as to increase neuronal metabolism of telemethylhistamine to an H2 agonist. Separately or in conjunction with the others, the histamine H3 antagonist may be administered so as to inhibit metabolism of the telemethylhistamine to an H3 agonist, thereby increasing metabolism of the telemethylhistamine to an H2 agonist. The increased histamine H2 agonist levels reduce demyelination and the symptoms that are associated with these conditions.
Owner:EAD
Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
Owner:JANSSEN PHARMA NV
Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
Thieno- and furo-pyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as inflammation.
Owner:JANSSEN PHARMA NV
Liquid pharmaceutical composition
This invention relates to new pharmaceutical compositions and methods for their preparation, and in particular it relates to taste-masked liquid compositions comprising a solution of a histamine H2-antagonist complexed with an alginate and also containing a humectant. The solution is buffered to a pH of between about 6 to 7. The inventive solution may be flavored and sweetened and preserved.
Owner:BRAINTREE LAB
Pyrazoles for the treatment of obesity and other CNS disorders
This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain pyrazole derivatives, their salts and solvates. These compounds have H3 histamine receptor binding activity. This invention also relates to pharmaceutical compositions containing these compounds and to a method of treating disorders in which histamine H3 receptor modulation is beneficial.
Owner:ATHERSYS
Combination of an h2-receptor antagonist, antacid, and alginic acid to treat episodic heartburn
InactiveUS20180140630A1Organic active ingredientsDigestive systemParoxysmal AFNK1 receptor antagonist
A combination of an antacid, alginate, and a histamine H2-receptor antagonist, and methods of using the same for providing fast and lasting relief of symptoms of episodic heartburn are provided.
Owner:WOLFE M MICHAEL
Cyclopropyl amines as modulators of the histamine H3 receptor
ActiveUS7687499B2Improve breathabilityImprove permeabilityOrganic active ingredientsSenses disorderHistamine H1 receptorDisease
Owner:JANSSEN PHARMA NV
Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases
ActiveUS20190070184A1Increase pharmacokinetic half-lifeEliminate side effectsHeterocyclic compound active ingredientsCardiovascular disorderSide effectHalf-life
Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H1-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a β2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.
Owner:CARDIX THERAPEUTICS LLC
Analyzing Histamine H4 Receptor-Mediated Effects In Whole Blood
Assay methods for analyzing whole blood to detect histamine H4 receptor-mediated effects, such as eosinophil shape change, cytoskeletal change, adhesion molecule up-regulation, or calcium flux are described. Such methods are useful in clinical and diagnostic applications.
Owner:KARLSSON LARS +3
Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
InactiveUS20140105851A1Effective treatmentDigestive systemSynthetic polymeric active ingredientsDiseaseHistamine h
Disclosed herein are novel compositions and methods for treating or preventing GI tract disorders and / or GERD-related respiratory disorders as well as protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H2-receptor antagonists, γ-aminobutyricacid-b (GABA-B) agonists, prodrugs of GABA-B agonists, and protease inhibitors.
Owner:IRONWOOD PHARMA
Method and compositions for reducing cardiac dysfunctions with a selective histamine H3 receptor agonist
The invention provides a method for reducing cardiac dysfunctions in a human. The method comprises administration to the human of an effective amount of a selective histamine H3 Receptor agonist. In one embodiment, the method comprises limiting the accumulation of intracellular sodium (Nai) by inhibiting the Na+ / H+ exchanger activity in the human having a cardiac dysfunction, or a predisposition to a cardiac dysfunction. In another embodiment the method comprises inhibiting the N-type Ca2+ channel to modulate the concentration of intracellular calcium. The invention also provides a pharmaceutical composition that includes a selective histamine H3 Receptor agonist with a pharmaceutical carrier.
Owner:CORNELL RES FOUNDATION INC
Heterocyclic Compounds
Owner:JANSSEN PHARMA NV
Method for treatment of neurodegenerative diseases and the effects of aging
InactiveUS20080003209A1Nervous disorderPeptide/protein ingredientsAutoimmune conditionAutoimmune disease
Owner:DELACK ELAINE A
Pharmaceutical compositions and methods of treating cardiovascular diseases
ActiveUS20190231786A1Cardiovascular disorderHeterocyclic compound active ingredientsVascular diseasePhosphodiesterase inhibitor
Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.
Owner:CARDIX THERAPEUTICS LLC
Treatment Of Stroke With Histamine H3 Inverse Agonists Or Histamine H3 Antagonists
Owner:MERCK & CO INC
Benzoimidazol-2-yl pyrimidine derivatives
Owner:JANSSEN PHARMA NV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com